Aclaris Therapeutics Inc (NASDAQ: ACRS) open the trading on Wednesday, with a bit cautious approach as it glided -13.73% to $3.96, before settling in for the price of $4.59 at the close. Taking a more long-term approach, ACRS posted a 52-week range of $0.77-$5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 74.29% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 20.67%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 41.73%. This publicly-traded company’s shares outstanding now amounts to $70.89 million, simultaneously with a float of $68.57 million. The organization now has a market capitalization sitting at $282.87 million. At the time of writing, stock’s 50-day Moving Average stood at $1.65, while the 200-day Moving Average is $1.32.
Aclaris Therapeutics Inc (ACRS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Diagnostics & Research industry. Aclaris Therapeutics Inc’s current insider ownership accounts for 4.01%, in contrast to 70.04% institutional ownership. According to the most recent insider trade that took place on Nov 19 ’24, this organization’s Director bought 666,666 shares at the rate of 2.25, making the entire transaction reach 1,499,998 in total value, affecting insider ownership by 710,030. Preceding that transaction, on Aug 05 ’24, Company’s 10% Owner bought 206,025 for 1.24, making the whole transaction’s value amount to 256,357. This particular insider is now the holder of 14,250,000 in total.
Aclaris Therapeutics Inc (ACRS) Earnings and Revenue Records
Aclaris Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 41.73% and is forecasted to reach -0.52 in the upcoming year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Let’s observe the current performance indicators for Aclaris Therapeutics Inc (ACRS). It’s Quick Ratio in the last reported quarter now stands at 7.03. The Stock has managed to achieve an average true range (ATR) of 0.46. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.45.
In the same vein, ACRS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.52, a figure that is expected to reach -0.25 in the next quarter, and analysts are predicting that it will be -0.52 at the market close of one year from today.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
[Aclaris Therapeutics Inc, ACRS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 72.17% While, its Average True Range was 0.60.
Raw Stochastic average of Aclaris Therapeutics Inc (ACRS) in the period of the previous 100 days is set at 70.12%, which indicates a major rise in contrast to 64.41% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 251.54% that was higher than 114.21% volatility it exhibited in the past 100-days period.
